The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010)

Chinese Medicine

Craig J Currie³  David Coghill²  Christopher Ll Morgan¹  Chris D Poole³  Sara Jenkins-Jones¹  Sarah E Holden³ 

[1] Global Epidemiology, Pharmatelligence, Cardiff Medicentre, Cardiff CF14 4UJ, UK;Division of Neuroscience, Medical Research Institute, University of Dundee, Dundee DD1 9SY, UK;Primary Care and Public Health, School of Medicine, The Pharma Research Centre, Cardiff Medicentre, Cardiff University, Cardiff CF14 4UJ, UK

关键词: Healthcare cost;    Incidence;    Prevalence;    CPRD;    ADHD;   

Others  :  790737
DOI  :  10.1186/1753-2000-7-34

 received in 2013-04-26, accepted in 2013-10-02,  发布年份 2013

【 摘 要 】

Background

Attention deficit/hyperactivity disorder (ADHD) is a common disorder that often presents in childhood and is associated with increased healthcare resource use. The aims of this study were to characterise the epidemiology of diagnosed ADHD in the UK and determine the resource use and financial costs of care.

Methods

For this retrospective, observational cohort study, patients newly diagnosed with ADHD between 1998 and 2010 were identified from the UK Clinical Practice Research Datalink (CPRD) and matched to a randomly drawn control group without a diagnosis of ADHD. The prevalence and incidence of diagnosed ADHD were calculated. Resource utilisation and corresponding financial costs post-diagnosis were estimated for general practice contacts, investigations, prescriptions, outpatient appointments, and inpatient admissions.

Results

Incidence of diagnosed ADHD (and percentage change using 1998 as a reference) increased from 6.9 per 100,000 population in 1998 to 12.2 per 100,000 (78%) in 2007 and then fell to 9.9 per 100,000 (44%) by 2009. The corresponding prevalence figures were 30.5, 88.9 (192%) and 81.5 (167%) per 100,000. Incidence and prevalence were higher in males than females. Mean annual total healthcare costs were higher for ADHD cases than controls (£1,327 versus £328 for year 1, £1,196 vs. £337 for year 2, £1,148 vs. £316 for year 3, £1,126 vs. £325 for year 4, and £1,112 vs. £361 for year 5).

Conclusions

The prevalence of diagnosed ADHD in routine practice in the UK was notably lower than in previous reports, and both prevalence and incidence of diagnosed ADHD in primary care have fallen since 2007. Financial costs were more than four times higher in those with ADHD than in those without ADHD.

【 授权许可】

   
2013 Holden et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ford T, Goodman R, Meltzer H: The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Psy 2003, 42:1203-1211.
• [2]Prescribing & medicines: medicines used in mental health. Financial years 2001/02 – 2010/11 http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/2011-09-27/2011-09-27-PrescribingMentalHealth-Summary.pdf?96236819029 webcite
• [3]Hospital prescribing, England 2010. http://www.ic.nhs.uk/pubs/hospre10 webcite
• [4]Harpin V a: The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005, 90(Suppl 1):i2-i7.
• [5]Bagwell CL, Molina BS, Pelham WE, Hoza B: Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2001, 40:1285-1292.
• [6]Kadesjo B, Gillberg C: The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiat 2001, 42:487-492.
• [7]Johnston C, Mash EJ: Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001, 4:183-207.
• [8]Ray GT, Levine P, Croen LA, Bokhari F, Hu T-W, Habel L: Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr & Adolesc Med 2006, 160:1063-1069.
• [9]Guevara J, Lozano P, Wickizer T, Mell L, Gephart H: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:71-78.
• [10]Leibson C, Katusic S, Barbaresi WJ, Ransom J, Brien PCO: Use and costs of medical care for children attention-deficit/hyperactivity disorder. JAMA 2001, 285:60-66.
• [11]Chan E, Zhan C, Homer CJ: Health care Use and costs for children with attention-deficit/hyperactivity disorder. Arch Pediat Adol Med 2002, 156:504-511.
• [12]Pelham WE, Foster EM, Robb J a: The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr 2007, 7(1 Suppl):121-131.
• [13]Matza LS, Paramore C, Prasad M: A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005, 3:5. BioMed Central Full Text
• [14]Birnbaum H, Kessler R, Lowe S, Secnik K, Greenberg P, Leong S, Swensen A: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005, 21:195-206.
• [15]Hakkaart-van Roijen L, Zwirs BWC, Bouwmans C, Tan SS, Schulpen TWJ, Vlasveld L, Buitelaar JK: Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adoles Psy 2007, 16:316-326.
• [16]ADHD: diagnosis and management of ADHD in children, young people and adults. NICE Clinical Guideline 72 http://www.nice.org.uk/nicemedia/pdf/adhdfullguideline.pdf webcite
• [17]Use of ADHD drugs “increases by 50% in six years” http://www.bbc.co.uk/news/health-23674235 webcite
• [18]ADHD services over Scotland final report http://www.healthcareimprovementscotland.org/our_work/mental_health/adhd_service_improvement/stage_3_adhd_final_report.aspx webcite
• [19]Clinical practice research datalink http://www.cprd.com/intro.asp webcite
• [20]Committee on Safety of Medicines and Medicines Control Agency: Volital (Pemoline) has been withdrawn. Current Problems in Pharmacovigilance 1997, 23:10.
• [21]British National Formulary (online) http://www.medicinescomplete.com webcite
• [22]Prescriptions cost analysis – England 2011. http://www.ic.nhs.uk/pubs/prescostanalysis2011 webcite
• [23]Prescribing http://www.hscic.gov.uk/prescribing webcite
• [24]Prescription cost analysis, England 2010. http://www.ic.nhs.uk/catalogue/PUB02274/pres-cost-anal-eng-2010-apx.pdf webcite
• [25]HM Treasury: Economic data and tools. Latest figures. http://www.hm-treasury.gov.uk/data_gdp_fig.htm webcite
• [26]Tariff information: confirmation of payment by results (PbR) arrangements for 2010–2011 http://data.gov.uk/dataset/payment-by-results-2010-11-national-tariff-information webcite
• [27]NHS reference costs 2010–2011 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140 webcite
• [28]Health Statistics Wales 2011 http://wales.gov.uk/topics/statistics/publications/publication-archive/health2011/?lang=en webcite
• [29]NHS National Services Scotland http://www.isdscotland.org/ webcite
• [30]NHS pathology: pathology solutions http://www.nhspathology.fph.nhs.uk/ webcite
• [31]Unit costs of health and social care 2011. http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf webcite
• [32]GP workload survey http://www.ic.nhs.uk/pubs/gpworkload webcite
• [33]Downloads: costing http://www.ic.nhs.uk/casemix/costing webcite
• [34]NHS Reference Costs 2009–2010 https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010 webcite
• [35]Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA: The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948.
• [36]Sayal K, Taylor E, Beecham J, Byrne P: Pathways to care in children at risk of attention-deficit hyperactivity disorder. Br J Psychiatry 2002, 181:43-48.
• [37]Sayal K, Goodman R, Ford T: Barriers to the identification of children with attention deficit/hyperactivity disorder. J Child Psychol Psychiatry 2006, 47:744-750.
• [38]Jick H, Kaye JA, Black C: Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract 2004, 54:345-347.
• [39]Klasen H, Goodman R: Parents and GPs at cross-purposes over hyperactivity: a qualitative study of possible barriers to treatment. Br J Gen Pract 2000, 50:199-202.
• [40]Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS: Prevalence, Recognition, and Treatment of Attention-Deficit/Hyperactivity Disorder in a National Sample of US Children. Arch Paediat Adol Med 2007, 161:857-864.
• [41]Morbidity and Mortality Weekly Report (MMWR). Increasing Prevalence of Parent-Reported Attention-Deficit/Hyperactivity Disorder Among Children - United States, 2003 and 2007 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm webcite
• [42]Attention Deficit and Hyperkinetic Disorders – Services Over Scotland (ADHD-SOS) Follow-up Review http://www.healthcareimprovementscotland.org/his/idoc.ashx?docid=c3c72452-cb24-4179-bdba-13be65b74c3d&version=−1 webcite
• [43]McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, De Soysa R, Taylor E, Williams T, Wong ICK: Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009, 194:273-277.
• [44]Kooij J, Buitelaar J, Van den Oord E, Furer J, Rijnders C, Hodiamont P: Internal and external validity of Attention-Deficit Hyperactivity Disorder in a population-based sample of adults. Psychol Med 2004, 34:1-11.
• [45]Berry CA, Shaywitz SE, Shaywitz BA: Girls with attention deficit disorder: a silent minority? A report on behavioral and cognitive characteristics. Pediatrics 1985, 76:801-809.
• [46]Pastor PN, Reuben C a: Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004–2006. Vital Health Stat 2008, 10:1-14.
• [47]Simon V, Czobor P, Bálint S, Mészáros A, Bitter I: Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194:204-211.
• [48]Faraone SV, Biederman J, Mick E: The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006, 36:159-165.
• [49]Office for National Statistics: Population estimates quinary age groups for UK constituent countries – mid 1971 to mid 2010. http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/population-estimates-timeseries-1971-to-current-year/index.html webcite
• [50]Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiat 2006, 163:716-723.
• [51]King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R: A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Asses 2006, 10:1-146.
• [52]Telford C, Green C, Logan S, Langley K, Thapar A, Ford T: Estimating the costs of ongoing care for adolescents with attention-deficit hyperactivity disorder. Soc Psychiatry Psychiatr Epidemiol 2013, 48:337-344.
• [53]Gallagher A, Puri S, Van Staa T: Linkage of the General Practice Research Database (GPRD) with other data sources. Pharmacoepidemiol Drug Saf 2011, 20:S1-S364.
• [54]Khan NF, Harrison SE, Rose PW: Validity of diagnostic coding within the General Practice Research Database : a systematic review. Brit J Gen Pract 2010, 60:e128-e136.
• [55]Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Brit J Clin Pharmaco 2010, 69:4-14.